-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Immunic, Lowers Price Target to $8

Benzinga·11/13/2025 13:47:21
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $10 to $8.